The EPS beat signals improving operational efficiency or revenue growth. Traders should watch the Q2 2026 earnings call on August 6 for guidance on XDEMVY sales and any pipeline updates, which could drive further upside.
Price Chart
Executive Summary
Tarsus Pharmaceuticals reported Q1 2026 EPS of -$0.16, beating the consensus estimate of -$0.20 by 18.4%, marking a notable earnings surprise. The company will host a webcast on August 6, 2026, to discuss Q2 2026 results and provide a corporate update, which may provide further insight into the trajectory of its commercial products like XDEMVY.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.16 beat consensus of -$0.20 by 18.4%
- Company to report Q2 2026 financial results on August 6, 2026
- Market cap of $2.6B with strong analyst consensus (93% bullish)
Financial Impact
EPS beat of 18.4% vs consensus
Risk Factors
- Commercial execution risk for XDEMVY
- Potential for future earnings misses given historical volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3339874 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $82.77 $77.64 | ▼ −6.20% | ▼ −5.54% | $73.61 (−11.06%) |
Sep 3, 2026 29d ago | Insider Cluster | $83.21 $79.31 | ▼ −4.68% | ▼ −3.53% | $73.61 (−11.53%) |
Sep 2, 2026 29d ago | 144 | $82.76 $81.12 | ▲ +1.98% | ▲ +1.02% | $73.61 (+11.05%) |
Sep 1, 2026 4w ago | 144 | $82.76 $81.12 | ▲ +1.98% | ▲ +1.02% | $73.61 (+11.05%) |
Aug 19, 2026 6w ago | 144 | $73.44 $70.65 | ▼ −3.80% | ▼ −3.41% | $73.61 (+0.24%) |
Aug 6, 2026 8w ago | 8-K | $65.33 $68.88 | ▲ +5.43% | ▲ +4.22% | $73.61 (+12.68%) |
Aug 6, 2026 8w ago | 8-K | $65.33 $68.88 | ▲ +5.43% | ▲ +4.22% | $73.61 (+12.68%) |
Aug 6, 2026 8w ago | 8-K | $65.33 $68.88 | ▲ +5.43% | ▲ +4.22% | $73.61 (+12.68%) |
Aug 6, 2026 8w ago | Press Release | $65.33 $68.88 | ▲ +5.43% | ▲ +4.22% | $73.61 (+12.68%) |
Aug 6, 2026 8w ago | Press Release | $65.33 $68.88 | ▲ +5.43% | ▲ +4.22% | $73.61 (+12.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access